2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1125

Fatigue In Ankylosing Spondylitis Is Associated With The Brain Networks Of Sensory Salience and Attention
Abstract Number: 2717

Fatigue in Rheumatoid Arthritis Is Associated With Modifiable Lifestyle Factors
Abstract Number: 885

Fatigue In SLE Is Associated With Upregulation Of Interferon- Alpha Related Gene Transcripts
Abstract Number: 751

Fatigue, Pain, and Functional Disability Among Patients With Vasculitis
Abstract Number: 2200

Fatty Acid Profiling In Juvenile Idiopathic Arthritis: The Balance Between Pro-Inflammatory and Pro-Resolving Prostanoids
Abstract Number: 1574

Favorable Clinical Response To Belimumab At Three Months
Abstract Number: 2808

Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants
Abstract Number: 178

Fc-Gamma Receptor Genetic Variation In Kawasaki Disease
Abstract Number: 1257

Feasibility and Clinical Implications Of The Pediatric Automated Neuropsychological Assessment Metrics for Screening Of Childhood-Onset Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 2631

Fertility In Behçet’s Syndrome: Structured Interview In A Multidisciplinary Center
Abstract Number: 73

Fibrillin-1 Expression and Function Is Needed For Normal Joint Function and Mutations Leads To Osteoarthritis
Abstract Number: 1088

Fibromyalgia and Parental Medical Histories Of Depression and Alcoholism
Abstract Number: 140

Fibromyalgia and Pregnancy: Challenges Of The Savella^® (Milnacipran) Pregnancy Registry
Abstract Number: 840

Fibromyalgia, Somatic Symptoms, and Mental Illness In View Of The 2013 Diagnostic and Statistical Manual Of Mental Disorders
Abstract Number: 64

Fibulin-3 In Joint Aging and Osteoarthritis Pathogenesis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].